Mesoblast Limited (MSB) Price & Analysis

Compare

281 Followers

MSB Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.92 - AU$3.37

Previous CloseN/A

Volume5.54M

Average Volume (3M)4.58M

Market Cap

$3.15B

Enterprise ValueAU$3.68B

Total Cash (Recent Filing)$38.03M

Total Debt (Recent Filing)$126.11M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Feb 26, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding1,279,967,200

10 Day Avg. Volume2,897,244

30 Day Avg. Volume4,583,098

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.17

Enterprise Value/Revenue649.63

Enterprise Value/Gross Profit-163.22

Enterprise Value/Ebitda-74.52

Forecast

1Y Price Target

$2.89

Price Target Upside15.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Mesoblast Limited News

Mesoblast reports FY25 net loss ($102.1M) vs. ($88.0M) last year

Reports FY25 revenue $17.2M vs. $5.9M last year. Mesoblast (MESO) CEO Dr. Silviu Itescu said, “This has been...

6h ago

MESO

Mesoblast options imply 11.6% move in share price post-earnings

Pre-earnings options volume in Mesoblast (MESO) is normal with calls leading puts 28:1. Implied volatility suggests the market...

10h ago

MESO

Mesoblast Limited Reports Progress and Financial Challenges

Mesoblast Limited ( ($MEOBF) ) has released its Q4 earnings. Here is a breakdown of the information Mesoblast...

3h ago

Mesoblast Achieves FDA Approval and Launches Ryoncil®

Mesoblast Limited ( ($AU:MSB) ) just unveiled an announcement. Mesoblast Limited announced a significant milestone with the FDA...

7h ago

Mesoblast Limited Announces Webcast on Fiscal Year 2025 Financial Results

Mesoblast Limited ( ($AU:MSB) ) has shared an update. Mesoblast Limited has announced a webcast to discuss its...

2d ago

State Street Global Advisors Ceases Substantial Holding in Mesoblast

The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast Limited has announced that State Street...

4d ago

State Street Corporation Ceases Substantial Holding in Mesoblast Limited

Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast Limited has announced that State Street Corporation and...

1M ago

JPMorgan Chase & Co. Reduces Stake in Mesoblast Limited

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. JPMorgan Chase & Co. and its affiliates...

1M ago

JPMorgan Acquires Substantial Stake in Mesoblast

Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. JPMorgan Chase & Co. and its affiliates have become...

1M ago

Mesoblast downgraded to Hold from Buy at Jefferies

Jefferies analyst David Stanton downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.60, up...

1M ago

MESO

Mesoblast reports Q1 Ryoncil gross revenue $13.2M

Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is...

1M ago

MESO

Mesoblast Reports Successful Launch of Ryoncil® and Expands Pipeline Efforts

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited announced the successful commercial launch...

1M ago

JPMorgan Acquires 5% Stake in Mesoblast Limited

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. JPMorgan Chase & Co. and its affiliates...

1M ago

Mesoblast Limited Announces Cessation of Securities

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited announced the cessation of 483,254...

2M ago

MSB FAQ

What was Mesoblast Limited’s price range in the past 12 months?

Mesoblast Limited lowest share price was AU$0.92 and its highest was AU$3.37 in the past 12 months.

What is Mesoblast Limited’s market cap?

Mesoblast Limited’s market cap is $3.15B.

When is Mesoblast Limited’s upcoming earnings report date?

Mesoblast Limited’s upcoming earnings report date is Feb 26, 2026 which is in 181 days.

How were Mesoblast Limited’s earnings last quarter?

Mesoblast Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.067 earnings per share for the quarter, missing the consensus estimate of -AU$0.057 by -AU$0.011.

Is Mesoblast Limited overvalued?

According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast Limited pay dividends?

Mesoblast Limited does not currently pay dividends.

What is Mesoblast Limited’s EPS estimate?

Mesoblast Limited’s EPS estimate is -0.04.

How many shares outstanding does Mesoblast Limited have?

Mesoblast Limited has 1,279,967,200 shares outstanding.

What happened to Mesoblast Limited’s price movement after its last earnings report?

Mesoblast Limited reported an EPS of -AU$0.067 in its last earnings report, missing expectations of -AU$0.057. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Mesoblast Limited?

Currently, no hedge funds are holding shares in AU:MSB

Mesoblast Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-21.31%

Trailing 12-Months

Asset Growth

-2.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mesoblast Limited

Mesoblast Limited (MSB) is a biopharmaceutical company specializing in the development of innovative cellular medicines. The company focuses on advanced therapeutic solutions for severe and life-threatening diseases, primarily in the areas of cardiovascular, inflammatory, and immune-mediated conditions. Mesoblast's core products are based on its proprietary mesenchymal lineage adult stem cell technology platform, which aims to harness the regenerative potential of stem cells to repair and regenerate damaged tissues.

Mesoblast Limited (MSB) Earnings & Revenues

Historic Earnings Reports

MSB Company Deck

MSB Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant achievements, particularly the FDA approval of RYONCIL and successful fundraising efforts. The company demonstrated robust clinical trial results across multiple programs with potential market expansion plans. However, the financial loss and challenges in trial enrollment were noted as areas needing attention.View all AU:MSB earnings summaries

MSB Stock 12 Month Forecast

Average Price Target

AU$2.89

▲(15.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"AU$4","-1":"-AU$1","0.25":"AU$0.25","1.5":"AU$1.5","2.75":"AU$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.4999999904079,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.8869113808,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$2.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4999999931485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.35,2.438461537723685,2.5269230754473693,2.615384613171054,2.7038461508947385,2.7923076886184233,2.8807692263421076,2.9692307640657924,3.057692301789477,3.1461538395131616,3.234615377236846,3.323076914960531,3.4115384526842156,{"y":3.4999999904079,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.35,2.391300875446154,2.432601750892308,2.473902626338462,2.5152035017846153,2.556504377230769,2.597805252676923,2.639106128123077,2.680407003569231,2.721707879015385,2.7630087544615387,2.804309629907692,2.845610505353846,{"y":2.8869113808,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.35,2.361538461011423,2.3730769220228463,2.3846153830342693,2.3961538440456924,2.4076923050571155,2.4192307660685386,2.4307692270799617,2.4423076880913848,2.453846149102808,2.465384610114231,2.476923071125654,2.488461532137077,{"y":2.4999999931485,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.295,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.995,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.935,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.595,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >